Neratinib CAS NO.698387-09-6

Min.Order Quantity:: 1 Kilogram

Purity:: 99%

Port:: China Main Port

Payment Terms:: L/C,T/T,

Add to Inquiry Cart

Product Details

Keywords

Neratinib
698387-09-6
Neratinib

Quick Details

ProName: Neratinib
CasNo: 698387-09-6
Molecular Formula: 698387-09-6
Appearance: NA
Application: Inorganic Chemicals
DeliveryTime: With about 7-10 days after receipt the...
PackAge: 1KG -200KG Drum with pallet
Port: China Main Port
ProductionCapacity: 1 Metric Ton/Week
Purity: 99%
Storage: NA
Transportation: by air
LimitNum: 1 Kilogram
Grade: Industrial Grade,Pharma Grade

Superiority

competitive price

high quality

fast delivery

custom-made

welcome to henan tianfu chemical co., ltd. website. our company engages in sodium tripolyphosphate (stpp) and sodium hexametabphosphate (shmp) production; development of noble metal catalysts, synthesis of electronic chemical materials and general chemicals imp&exp trading business. the company is located in zhengzhou high-tech development zone with import and export license. we passed iso 9001:2008 in 2009, and won "high-tech enterprise" by provincial government in 2013. our stpp and shmp has reached an annual output of 30000 tons and has successfully passed sgs, ciq audits on many occasions.

in 2011 we entered the fine chemical market of noble metal catalyst ,organic phosphine ligands and oled intermediates.with the joint efforts of our senior experts and professional technicians, tianfu has developed more than 500 compounds, which are widely used in the fields of production and life science. the objective of the company is to put quality first and put our customer’s needs first - the satisfaction of our customers is the company's ultimate goal. improving product quality and service level is our responsibility, and creating more value for our customer’s is our purpose. we are constantly striving to make henan tianfu a leading chemical supplier, and hope to create a better future with you.

Details

neratinib basic information

new anticancer drug synthesis pathways side effect

product name:	neratinib
synonyms:	(2e)-n-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;neratinib;(e)-n-[4-[3-chloro-4-[(2-pyridinyl)methoxy]anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide;(2e)-n-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;n-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide;unii-jjh94r3pwb;neratinib(hki-272);(2e)-n-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
cas:	698387-09-6
mf:	c30h29cln6o3
mw:	557.04266
einecs:
product categories:	antineoplastic;anti-cancer & immunity;inhibitors
mol file:	698387-09-6.mol

neratinib chemical properties

density

1.33

safety information

msds information

neratinib usage and synthesis

new anticancer drug	neratinib developed by us wyeth company is an irreversible epidermal growth factor receptor(egfr) inhibitor. it is a multiple target point of small molecule tyrosine kinase inhibitors to her 2 and her1 after lapatinib, and is an irreversible erbb receptor tyrosine kinase inhibitor. neratinib could selectively inhibit her-1 and her-2 of egfr family(ic50 was 92 nmol/l and 59 nmol/l, respectively). clinical research showed that neratinib exerted significant therapeutic effect on non-small cell lung cancer, colon cancer, and breast cancer. the phaseⅱclinical trial indicated that neratinib showed good efficacy and tolerance to her-2 positive patients with advanced breast cancer who had been received or not trastuzumab treatment. the phase ⅲ breast cancer clinical trial was complete in september 2014. the data indicated that the efficacy of neratinib was better than roche's herceptin in treatment of her-2 positive early breast cancer. the above information is edited by the chemicalbook of liu yujie.
synthesis pathways	3-chloro-4- (pyridin-2-yl-methoxy) - aniline (2) and n- (4- chloro-3-cyano-7-ethoxy-quinolin-6-yl) - acetamide (3) are used as raw material to prepare n- [4- [3- chloro-4- (pyridin-2-yl-methoxy) anilino] -3-cyano-7-ethoxy-quinolin-6-yl] acetamide (4) by nucleophilic substitution. deprotection of 4 was under the effect of hydrochloric acid, then was precipitated the free base in methanol solution of potassium carbonate to prepare 6-amino-3-cyano-4- [3-chloro-4- (pyridin-2-yl-methoxy) anilino] -7-ethoxy-quinoline (5). neratinib(1) was obtained by condensation of 5 and acyl chloride which was prepared by trans-4-dimethylamino-crotonic acid hydrochloride (6). figure 1 synthesis pathways of neratinib
side effect	diarrhea, nausea, vomiting, and fatigue.
usage	neratinib (hki-272) is a highly selective her2 and egfr inhibitor with ic50 of 59 nm and 92 nm, respectively.
usage	an oral, irreversible dual egfr/her2 inhibitor for breast and non-small cell lung cancer. antitumor agent